Jatinder Lamba

Dr. Jatinder Lamba

University of Florida
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Jatinder LambaJatinder Lamba
Jatinder Lamba
LCLata Chauhan
Lata Chauhan
MSMiyoung Shin
Miyoung Shin
MLMichael R. Loken
Michael R. Loken
JPJessica A. Pollard
Jessica A. Pollard
SMSoheil Meshinchi
Soheil Meshinchi
Purpose: Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism rs12459419 C>T in the splice enhancer region regulates the expression of an alternatively spliced CD33 isoform lacking exon2 (D2-CD33), thus eliminating the CD33 IgV domain, which is the antibody-binding site for GO, as well as diagnostic immunophenotypic panels. We aimed to determine the impact of the genotype of this splicing polymorphism in patients with AML treated with GO-containing chemotherapy. Patients and Methods: CD33 splicing single nucleotide polymorphism was evaluated in newly diagnosed patients with AML randomly assigned to receive standard five-course chemotherapy alone (No-GO arm, n = 408) or chemotherapy with the addition of two doses of GO once during induction and once during intensification (GO arm, n = 408) as per the Children’s Oncology Group AAML0531 trial. Results: The rs12459419 genotype was CC in 415 patients (51%), CT in 316 patients (39%), and TT in 85 patients (10%), with a minor allele frequency of 30%. The T allele was significantly associated with higher levels of D2-CD33 transcript ( P < 1.0E−6) and with lower diagnostic leukemic cell surface CD33 intensity ( P < 1.0E−6). Patients with the CC genotype had significantly lower relapse risk in the GO arm than in the No-GO arm (26% v 49%; P < .001). However, in patients with the CT or TT genotype, exposure to GO did not influence relapse risk (39% v 40%; P = .85). Disease-free survival was higher in patients with the CC genotype in the GO arm than in the No-GO arm (65% v 46%, respectively; P = .004), but this benefit of GO addition was not seen in patients with the CT or TT genotype. Conclusion: Our results suggest that patients with the CC genotype for rs12459419 have a substantial response to GO, making this a potential biomarker for the selection of patients with a likelihood of significant response to GO.

23 October 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
AEAbdelrahman H. Elsayed
Abdelrahman H. Elsayed
RRRoya Rafiee
Roya Rafiee
XCXueyuan Cao
Xueyuan Cao
SRSusana Raimondi
Susana Raimondi
JDJames R. Downing
James R. Downing
Jatinder LambaJatinder Lamba
Jatinder Lamba

3 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BSBradley Stockard
Bradley Stockard
TGTimothy Garrett
Timothy Garrett
JGJoy Guingab-Cagmat
Joy Guingab-Cagmat
SMSoheil Meshinchi
Soheil Meshinchi
Jatinder LambaJatinder Lamba
Jatinder Lamba
Acute myeloid leukemia (AML) is a heterogeneous disease with dismal response warranting the need for enhancing our understanding of AML biology. One prognostic feature associated with inferior response is the presence of activating mutations in FMS-like tyrosine kinase 3 (FLT3) especially occurrence of internal tandem duplication (FLT3-ITD). Although poorly understood, differential metabolic and signaling pathways associated with FLT3-ITD might contribute towards the observed poor prognosis. We performed a non-targeted global metabolic profiling of matched cell and plasma samples obtained at diagnosis to establish metabolic differences within FLT3-ITD and FLT3-WT pediatric AML. Metabolomic profiling by Ultra-High Performance-Liquid-Chromatography–Mass Spectrometry identified differential abundance of 21 known metabolites in plasma and 33 known metabolites in leukemic cells by FLT3 status. These metabolic features mapped to pathways of significant biological importance. Of interest were metabolites with roles in cancer, cell progression and involvement in purine metabolism and biosynthesis, cysteine/methionine metabolism, tryptophan metabolism, carnitine mediated fatty acid oxidation, and lysophospholipid metabolism. Although validation in a larger cohort is required, our results for the first time investigated global metabolic profile in FLT3-ITD AML.

1 June 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
Jatinder LambaJatinder Lamba
Jatinder Lamba
XCXueyuan Cao
Xueyuan Cao
SRSusana C. Raimondi
Susana C. Raimondi
RRRoya Rafiee
Roya Rafiee
JDJames R. Downing
James R. Downing
SPStanley B. Pounds
Stanley B. Pounds
Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia

9 September 2021 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
MFMaarten Fornerod
Maarten Fornerod
JMJing Ma
Jing Ma
SNSanne Noort
Sanne Noort
YLYu Liu
Yu Liu
MWMichael P. Walsh
Michael P. Walsh
TGTanja A. Gruber
Tanja A. Gruber
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification. Significance: Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes. This article is highlighted in the In This Issue feature, p. 549

21 May 2019 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
RRRoya Rafiee
Roya Rafiee
LCLata Chauhan
Lata Chauhan
TATodd A. Alonzo
Todd A. Alonzo
YWYi-Cheng Wang
Yi-Cheng Wang
AEAhlam Elmasry
Ahlam Elmasry
Jatinder LambaJatinder Lamba
Jatinder Lamba
Gemtuzumab-ozogamicin (GO), a humanized-anti-CD33 antibody linked with the toxin-calicheamicin-γ is a reemerging and promising drug for AML. Calicheamicin a key element of GO, induces DNA-damage and cell-death once the linked CD33-antibody facilitates its uptake. Calicheamicin efflux by the drug-transporter PgP-1 have been implicated in GO response thus in this study, we evaluated impact of ABCB1-SNPs on GO response. Genomic-DNA samples from 942 patients randomized to receive standard therapy with or without addition of GO (COG-AAML0531) were genotyped for ABCB1-SNPs. Our most interesting results show that for rs1045642, patients with minor-T-allele (CT/TT) had better outcome as compared to patients with CC genotype in GO-arm (Event-free survival-EFS: p = 0.022; and risk of relapse-RR, p = 0.007). In contrast, no difference between genotypes was observed for any of the clinical endpoints within No-GO arm (all p > 0.05). Consistent results were obtained when genotype groups were compared by GO and No-GO arms. The in vitro evaluation using HL60-cells further demonstrated consistent impact of rs1045642-T-allele on calicheamicin induced DNA-damage and cell-viability. Our results show the significance of ABCB1 SNPs on GO response in AML and warrants the need to investigate this in other cohorts. Once validated, ABCB1-SNPs in conjunction with CD33-SNPs can open up opportunities to personalize GO-therapy.